BridgeBio's dwarfism data Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 12 February, 2026

After years of rough sledding, biotech investors are getting back to work. Join us for a data-driven look at the field’s top VCs and their strategies for 2026. Get your spot now.

presented by 7 Re­al-World Ways RWE Is Trans­form­ing Health­care

spotlight In Focus More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem

news In a first, one CAR-T therapy is going up directly against another in trial Updated: Sanofi's Paul Hudson out, with Belén Garijo to step in as new CEO BridgeBio's dwarfism drug succeeds in Phase 3, adding to recent late-stage wins Utah startup Leash Bio warns AI models 'cheat' in biology. It bets its own 'dinky' model shows the way forward European VCs form coalition to garner support for homegrown biotech investing Watch: Is biotech’s relationship with the FDA at a breaking point?

CGT has fresh momentum from new FDA frameworks and pharma deals, but do the latest advances in science, manufacturing, and regulation actually solve the core challenges? We’re asking the hard questions — join us.

Client Engagement Mgr - Life Sciences Strategy & Intelligence Sedulo Group United States Vice President, Drug Metabolism & Pharmacokinetics (DMPK) C4 Therapeutics Watertown, MA, USA Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

in case you missed it 1. FDA may be more open to Moderna’s flu shot in a narrower population, senior official says •  Prasad overruled vaccine review team, office director on Moderna flu shot 2. Exclusive: Sanofi invests in China startup developing molecular glue for sickle cell disease 3. Former AstraZeneca senior staff charged with illegal trade in China 4. Madrigal bolsters MASH pipeline with deal for six siRNAs from China-based Ribo 5. News Briefing Gubra forms venture unit; Galecto's $275M offering 6. In wake of CEO ouster, CSL details profit crash and $1.1B charge on lower US vaccine demand 7. Updated: Upstream Bio's stock slides on Phase 2 severe asthma data 8. Why Washington’s all-in on smart rings 9.